Literature DB >> 9459141

Suppression of matrix metalloproteinase-2-mediated cell invasion in U87MG, human glioma cells by anti-microtubule agent: in vitro study.

D Yoshida1, J M Piepmeier, T Bergenheim, R Henriksson, A Teramoto.   

Abstract

Because microtubules are important components of cell motility and intracellular transport, it is reasonable to propose that the depolymerizing effect of an antimicrotubule agent, estramustine, on glioma microtubules would modulate cell invasiveness. To determine whether matrix metalloproteinases, key factors in cell invasion, are affected by exposure to estramustine, a cell proliferation assay, a zymogram, a collagenolysis assay and a haptoinvasion assay were used in this study. The zymogram revealed that an activated (62 kDa) form of matrix metalloproteinase-2 diminished with increasing estramustine concentrations. The collagenolysis assay demonstrated approximately 2.5- to 21-fold lower rates of enzymatic activity suppressed by estramustine in a dose-dependent manner at estramustine concentrations of 1, 5, and 10 microM, compared with the control group. On the haptoinvasion assay, no statistically significant difference was seen in the 0.5 microM estramustine group, whereas 1-10 microM estramustine groups revealed significant suppression of invasion from 6 to 24 h in a dose-dependent manner. The results suggest that estramustine suppresses the invasion of U87MG cells in vitro using the decreasing available matrix metalloproteinase-2, an effect caused by the disassembly of microtubules. Suppression of the infiltrative capacity of malignant glioma cells could be of significant value in the treatment of this disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9459141      PMCID: PMC2151249          DOI: 10.1038/bjc.1998.4

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  40 in total

1.  C6 glioma-astrocytoma cell and fetal astrocyte migration into artificial basement membrane: a permissive substrate for neural tumors but not fetal astrocytes.

Authors:  J J Bernstein; E R Laws; K V Levine; L R Wood; G Tadvalkar; W J Goldberg
Journal:  Neurosurgery       Date:  1991-05       Impact factor: 4.654

2.  A rapid in vitro assay for quantitating the invasive potential of tumor cells.

Authors:  A Albini; Y Iwamoto; H K Kleinman; G R Martin; S A Aaronson; J M Kozlowski; R N McEwan
Journal:  Cancer Res       Date:  1987-06-15       Impact factor: 12.701

3.  Human astrocytes proliferate in response to tumor necrosis factor alpha.

Authors:  B P Barna; M L Estes; B S Jacobs; S Hudson; R M Ransohoff
Journal:  J Neuroimmunol       Date:  1990-12       Impact factor: 3.478

4.  Cytoskeleton in TFG-beta- and bFGF-modulated endothelial monolayer repair.

Authors:  B L Coomber
Journal:  Exp Cell Res       Date:  1991-05       Impact factor: 3.905

5.  Estramustine binding protein in human brain-tumor tissue.

Authors:  E von Schoultz; T Bergenheim; K Grankvist; R Henriksson
Journal:  J Neurosurg       Date:  1991-06       Impact factor: 5.115

6.  Effects of estramustine and its constituents on human malignant glioma cells.

Authors:  E von Schoultz; E Lundgren; R Henriksson
Journal:  Anticancer Res       Date:  1990 May-Jun       Impact factor: 2.480

7.  In vitro inhibition of cell proliferation, viability, and invasiveness in U87MG human glioblastoma cells by estramustine phosphate.

Authors:  D Yoshida; J M Piepmeier; A Teramoto
Journal:  Neurosurgery       Date:  1996-08       Impact factor: 4.654

8.  Uptake, metabolism and antiproliferative effect of estramustine phosphate in human glioma cell lines.

Authors:  E von Schoultz; P O Gunnarsson; R Henriksson
Journal:  Anticancer Res       Date:  1989 Nov-Dec       Impact factor: 2.480

9.  Evidence that estramustine binds MAP-1A to inhibit type IV collagenase secretion.

Authors:  M E Stearns; M Wang; O Sousa
Journal:  J Cell Sci       Date:  1991-01       Impact factor: 5.285

10.  Raised levels of latent collagenase activating angiogenesis factor (ESAF) are present in actively growing human intracranial tumours.

Authors:  C M Taylor; J B Weiss; R H Lye
Journal:  Br J Cancer       Date:  1991-07       Impact factor: 7.640

View more
  9 in total

1.  Suppression of cell invasion on human malignant glioma cell lines by a novel matrix-metalloproteinase inhibitor SI-27: in vitro study.

Authors:  M Noha; D Yoshida; K Watanabe; A Teramoto
Journal:  J Neurooncol       Date:  2000-07       Impact factor: 4.130

2.  Dissecting and rebuilding the glioblastoma microenvironment with engineered materials.

Authors:  Kayla J Wolf; Joseph Chen; Jason Coombes; Manish K Aghi; Sanjay Kumar
Journal:  Nat Rev Mater       Date:  2019-08-16       Impact factor: 66.308

3.  Regulation of MMP-9 (type IV collagenase) production and invasiveness in gliomas by the extracellular signal-regulated kinase and jun amino-terminal kinase signaling cascades.

Authors:  S S Lakka; S L Jasti; A P Kyritsis; W K Yung; F Ali-Osman; G L Nicolson; J S Rao
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

4.  Inhibition of cell invasion by indomethacin on glioma cell lines: in vitro study.

Authors:  Maode Wang; Daizo Yoshida; Shouxun Liu; Akira Teramoto
Journal:  J Neurooncol       Date:  2005-03       Impact factor: 4.130

5.  The bleb formation of the extracellular pseudopodia; early evidence of microtubule depolymerization by estramustine phosphate in glioma cell; in vitro study.

Authors:  D Yoshida; M Noha; K Watanabe; T Bergenheim; R Henriksson; A Teramoto
Journal:  J Neurooncol       Date:  2001-03       Impact factor: 4.130

6.  Suppression of matrix metalloproteinase-2 and -9 mediated invasiveness by a novel matrix metalloproteinase inhibitor, BE16627B.

Authors:  K Watanabe; D Yoshida; M Noha; A Teramoto
Journal:  J Neurooncol       Date:  2001-03       Impact factor: 4.130

7.  Drug-induced apoptosis by anti-microtubule agent, estramustine phosphate on human malignant glioma cell line, U87MG; in vitro study.

Authors:  D Yoshida; S Hoshino; T Shimura; H Takahashi; A Teramoto
Journal:  J Neurooncol       Date:  2000-04       Impact factor: 4.130

8.  Induction of apoptosis by estramustine phosphate mediated by phosphorylation of bcl-2.

Authors:  D Yoshida; M Noha; K Watanabe; H Takahashi; Y Sugisaki; A Teramoto
Journal:  J Neurooncol       Date:  2001-08       Impact factor: 4.130

9.  Pilot study of estramustine added to radiosurgery and radiotherapy for treatment of high grade glioma.

Authors:  Howard Landy; Arnold Markoe; Priscilla Potter; Garrett Lasalle; Angela Marini; Niramol Savaraj; Isildinha Reis; Deborah Heros; Medhi Wangpaichitr; Lynn Feun
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.